

12-23-2003

12/19/03



EET

102630466

To the Honorable Commissioner for Patents. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):  
1) Jean Rapin 2) Hans Klaus Witzmann  
3) Jean-Marie Grumel and 4) Jacques Gonella

2. Name and address of receiving party(ies):

Name: **NEUROTELL AG**

Address: **Seestrasse 91**

Additional name(s) of conveying party(ies) attached?  Yes  No

3. Nature of conveyance:  
 Assignment  Merger  
 Security Agreement  Change of Name  
 Other \_\_\_\_\_

City: **Hergiswil** Country: **Switzerland** ZIP: **CH-6052**

Execution Date:  
1) 11/13/03 2) 11/19/03 3) 11/14/03 4) 11/11/03

Additional name(s) & address(es) attached?  Yes  No

4(a). Patent Application No.(s): 10/635,808

4(b). Patent No.(s):

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

Additional numbers attached?  Yes  No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: **Madeline I. Johnston, Esq.**

Address: **KING & SPALDING LLP  
45<sup>th</sup> Floor, 191 Peachtree Street, N.E.  
Atlanta, Georgia 30303**

6. Total number of applications and patents involved: **1**

7. Total fee (37 CFR 3.41) enclosed: **\$ 40.00**

**DO NOT USE THIS SPACE**

8. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*

*I certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Assignment Recordation Services, Director of the U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date given below.*

**Madeline I. Johnston**

Name of Person Signing

*Madeline Johnston*  
Signature

12/17/03  
Date

Attorney Docket No: 10945.105004 (Neuro 103)

Total number of pages including cover sheet: **9**

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services  
Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

12/22/2003 DBYRNE 00000216 10635808

01 FC:8021

40.00 OP

**ASSIGNMENT**

---


WHEREAS, we, **JEAN RAPIN, KLAUS HANS WITZMANN, JEAN-MARIE GRUMEL,** and **JACQUES GONELLA**, a citizen of France, residing at 9 square de Chatillon, F-75014 Paris, France; a citizen of Germany, residing at Lichtberg 2, D-84546 Egglkofen, Germany; a citizen of France, residing at 8 Avenue Honoré Esplette, F-69160 Tassin la Demi-Lune, France; and a citizen of Switzerland, residing at Obrechtstrasse 30, CH-4132 Muttenz, Switzerland; have invented certain inventions and improvements disclosed in an application for Letters Patent entitled "*Tripeptide Derivatives for the Treatment of Postlesional Diseases of the Nervous System*" filed in the United States Patent and Trademark Office on August 5, 2003, and assigned U.S. Application No. 10/635,808; which claims priority to German Patent Application No. 101 05 040.2 filed February 5, 2001, and PCT Patent Application No. PCT/EP02/01182 filed February 5, 2002, which is International Publication No. WO 02/062372 publication date, August 15, 2002; and

WHEREAS, **NEUROTELL AG**, Switzerland company having an office at Seestrasse 91, CH-6052 Hergiswil, Switzerland is desirous of acquiring an interest in the same.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which we hereby acknowledge, we, **JEAN RAPIN, KLAUS HANS WITZMANN, JEAN-MARIE GRUMEL,** and **JACQUES GONELLA**, by these presents do sell, assign, and transfer unto **NEUROTELL AG**, the full, exclusive, and entire right, title, and interest in and to said application, in and to any divisions, continuations, and reissues thereof, and in and to all inventions and improvements disclosed and described in said application, preparatory to obtaining Letters Patent of the United States therefor; and we hereby request the Director of the U.S. Patent and Trademark Office to issue any and all Letters Patent of the United States resulting from said application, or from a division, continuation, or reissue thereof, to **NEUROTELL AG** as the assignee, for its interest and for the sole use and benefit of **NEUROTELL AG** and its assigns and legal representatives;

For the same consideration, we, by these presents do sell, assign, and transfer to **NEUROTELL AG**, the full, exclusive, and entire right, title, and interest in and to any foreign application or applications corresponding to said application, in whole or in part, in countries other than the United States, in and to any Letters Patent and similar protective rights granted on said foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations; said foreign applications to be filed and issued in the name of **NEUROTELL AG**, or its designee insofar as permitted by applicable law;

AND, for the same consideration, we agree to sign all lawful papers, execute all division, continuing, reissue, and other applications, make all assignments and rightful oaths, and generally do everything possible to aid **NEUROTELL AG**, its successors, assigns, and nominees to obtain and enforce proper protection for all said inventions and improvements in all countries throughout the world.

 13 Nov. 2008

\_\_\_\_\_  
**JEAN RAPIN**

  
\_\_\_\_\_  
**KLAUS HANS WITZMANN**

  
\_\_\_\_\_  
**JEAN-MARIE GRUMEL**

  
\_\_\_\_\_  
**JACQUES GONELLA**

K&S Docket No.: NEURO 103

90 522 a/sep/11

## ASSIGNMENT

---

WHEREAS, we, **JEAN RAPIN**, **KLAUS HANS WITZMANN**, **JEAN-MARIE GRUMEL**, and **JACQUES GONELLA**, a citizen of France, residing at 9 square de Chatillon, F-75014 Paris, France; a citizen of Germany, residing at Lichtberg 2, D-84546 Egglkofen, Germany; a citizen of France, residing at 8 Avenue Honoré Esplette, F-69160 Tassin la Demi-Lune, France; and a citizen of Switzerland, residing at Obrechtstrasse 30, CH-4132 Muttenz, Switzerland; have invented certain inventions and improvements disclosed in an application for Letters Patent entitled "*Tripeptide Derivatives for the Treatment of Postlesional Diseases of the Nervous System*" filed in the United States Patent and Trademark Office on August 5, 2003, and assigned U.S. Application No. 10/635,808; which claims priority to German Patent Application No. 101 05 040.2 filed February 5, 2001, and PCT Patent Application No. PCT/EP02/01182 filed February 5, 2002, which is International Publication No. WO 02/062372 publication date, August 15, 2002; and

WHEREAS, **NEUROTELL AG**, Switzerland company having an office at Seestrasse 91, CH-6052 Hergiswil, Switzerland is desirous of acquiring an interest in the same.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which we hereby acknowledge, we, **JEAN RAPIN**, **KLAUS HANS WITZMANN**, **JEAN-MARIE GRUMEL**, and **JACQUES GONELLA**, by these presents do sell, assign, and transfer unto **NEUROTELL AG**, the full, exclusive, and entire right, title, and interest in and to said application, in and to any divisions, continuations, and reissues thereof, and in and to all inventions and improvements disclosed and described in said application, preparatory to obtaining Letters Patent of the United States therefor; and we hereby request the Director of the U.S. Patent and Trademark Office to issue any and all Letters Patent of the United States resulting from said application, or from a division, continuation, or reissue thereof, to **NEUROTELL AG** as the assignee, for its interest and for the sole use and benefit of **NEUROTELL AG** and its assigns and legal representatives;

For the same consideration, we, by these presents do sell, assign, and transfer to **NEUROTELL AG**, the full, exclusive, and entire right, title, and interest in and to any foreign application or applications corresponding to said application, in whole or in part, in countries other than the United States, in and to any Letters Patent and similar protective rights granted on said foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations; said foreign applications to be filed and issued in the name of **NEUROTELL AG**, or its designee insofar as permitted by applicable law;

AND, for the same consideration, we agree to sign all lawful papers, execute all division, continuing, reissue, and other applications, make all assignments and rightful oaths, and generally do everything possible to aid **NEUROTELL AG**, its successors, assigns, and nominees to obtain and enforce proper protection for all said inventions and improvements in all countries throughout the world.

---

**JEAN RAPIN**

*H. K. Witzmann 19. M. 2003*

---

**KLAUS HANS WITZMANN**

---

**JEAN-MARIE GRUMEL**

---

**JACQUES GONELLA**

K&S Docket No.: NEURO 103

**ASSIGNMENT**

---

WHEREAS, we, **JEAN RAPIN, KLAUS HANS WITZMANN, JEAN-MARIE GRUMEL**, and **JACQUES GONELLA**, a citizen of France, residing at 9 square de Chatillon, F-75014 Paris, France; a citizen of Germany, residing at Lichtberg 2, D-84546 Eggkofen, Germany; a citizen of France, residing at 8 Avenue Honoré Esplette, F-69160 Tassin la Demi-Lune, France; and a citizen of Switzerland, residing at Obrechtstrasse 30, CH-4132 Muttenz, Switzerland; have invented certain inventions and improvements disclosed in an application for Letters Patent entitled "*Tripeptide Derivatives for the Treatment of Postlesional Diseases of the Nervous System*" filed in the United States Patent and Trademark Office on August 5, 2003, and assigned U.S. Application No. 10/635,808; which claims priority to German Patent Application No. 101 05 040.2 filed February 5, 2001, and PCT Patent Application No. PCT/EP02/01182 filed February 5, 2002, which is International Publication No. WO 02/062372 publication date, August 15, 2002; and

WHEREAS, **NEUROTELL AG**, Switzerland company having an office at Seestrasse 91, CH-6052 Hergiswil, Switzerland is desirous of acquiring an interest in the same.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which we hereby acknowledge, we, **JEAN RAPIN, KLAUS HANS WITZMANN, JEAN-MARIE GRUMEL**, and **JACQUES GONELLA**, by these presents do sell, assign, and transfer unto **NEUROTELL AG**, the full, exclusive, and entire right, title, and interest in and to said application, in and to any divisions, continuations, and reissues thereof, and in and to all inventions and improvements disclosed and described in said application, preparatory to obtaining Letters Patent of the United States therefor; and we hereby request the Director of the U.S. Patent and Trademark Office to issue any and all Letters Patent of the United States resulting from said application, or from a division, continuation, or reissue thereof, to **NEUROTELL AG** as the assignee, for its interest and for the sole use and benefit of **NEUROTELL AG** and its assigns and legal representatives;

For the same consideration, we, by these presents do sell, assign, and transfer to **NEUROTELL AG**, the full, exclusive, and entire right, title, and interest in and to any foreign application or applications corresponding to said application, in whole or in part, in countries other than the United States, in and to any Letters Patent and similar protective rights granted on said foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations; said foreign applications to be filed and issued in the name of **NEUROTELL AG**, or its designee insofar as permitted by applicable law;

AND, for the same consideration, we agree to sign all lawful papers, execute all division, continuing, reissue, and other applications, make all assignments and rightful oaths, and generally do everything possible to aid **NEUROTELL AG**, its successors, assigns, and nominees to obtain and enforce proper protection for all said inventions and improvements in all countries throughout the world.

  
\_\_\_\_\_  
**JEAN RAPIN**

  
\_\_\_\_\_  
**KLAUS HANS WITZMANN**

 11/14/03  
\_\_\_\_\_  
**JEAN-MARIE GRUMEL**

  
\_\_\_\_\_  
**JACQUES GONELLA**

K&S Docket No.: NEURO 103

## ASSIGNMENT

---

WHEREAS, we, **JEAN RAPIN, KLAUS HANS WITZMANN, JEAN-MARIE GRUMEL**, and **JACQUES GONELLA**, a citizen of France, residing at 9 square de Chatillon, F-75014 Paris, France; a citizen of Germany, residing at Lichtberg 2, D-84546 Egglkofen, Germany; a citizen of France, residing at 8 Avenue Honoré Esplette, F-69160 Tassin la Demi-Lune, France; and a citizen of Switzerland, residing at Obrechtstrasse 30, CH-4132 Muttenz, Switzerland; have invented certain inventions and improvements disclosed in an application for Letters Patent entitled "*Tripeptide Derivatives for the Treatment of Postlesional Diseases of the Nervous System*" filed in the United States Patent and Trademark Office on August 5, 2003, and assigned U.S. Application No. 10/635,808; which claims priority to German Patent Application No. 101 05 040.2 filed February 5, 2001, and PCT Patent Application No. PCT/EP02/01182 filed February 5, 2002, which is International Publication No. WO 02/062372 publication date, August 15, 2002; and

WHEREAS, **NEUROTELL AG**, Switzerland company having an office at Seestrasse 91, CH-6052 Hergiswil, Switzerland is desirous of acquiring an interest in the same.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which we hereby acknowledge, we, **JEAN RAPIN, KLAUS HANS WITZMANN, JEAN-MARIE GRUMEL**, and **JACQUES GONELLA**, by these presents do sell, assign, and transfer unto **NEUROTELL AG**, the full, exclusive, and entire right, title, and interest in and to said application, in and to any divisions, continuations, and reissues thereof, and in and to all inventions and improvements disclosed and described in said application, preparatory to obtaining Letters Patent of the United States therefor; and we hereby request the Director of the U.S. Patent and Trademark Office to issue any and all Letters Patent of the United States resulting from said application, or from a division, continuation, or reissue thereof, to **NEUROTELL AG** as the assignee, for its interest and for the sole use and benefit of **NEUROTELL AG** and its assigns and legal representatives;


For the same consideration, we, by these presents do sell, assign, and transfer to **NEUROTELL AG**, the full, exclusive, and entire right, title, and interest in and to any foreign application or applications corresponding to said application, in whole or in part, in countries other than the United States, in and to any Letters Patent and similar protective rights granted on said foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations; said foreign applications to be filed and issued in the name of **NEUROTELL AG**, or its designee insofar as permitted by applicable law;

AND, for the same consideration, we agree to sign all lawful papers, execute all division, continuing, reissue, and other applications, make all assignments and rightful oaths, and generally do everything possible to aid **NEUROTELL AG**, its successors, assigns, and nominees to obtain and enforce proper protection for all said inventions and improvements in all countries throughout the world.

  
\_\_\_\_\_  
**JEAN RAPIN**

  
\_\_\_\_\_  
**KLAUS HANS WITZMANN**

  
\_\_\_\_\_  
**JEAN-MARIE GRUMEL**

 11.11.03  
\_\_\_\_\_  
**JACQUES GONELLA**

K&S Docket No.: NEURO 103